Generic drug
Nevirapine price, strengths & recalls
Pharmacies pay $4.41 for 30 tablets of Nevirapine 200 mg tablet this week, and from $4.41 to $49.03 across its 2 priced strengths and forms. 6 manufacturers make it. It has 2 recalls on record, none ongoing. Its official label last changed on August 5, 2022.
Generic- Fair cash price
- $15.57
- Strengths
- 2
- Makers
- 6
- Updated
- Nov 11
Nevirapine price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for 30 tablets. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 400 mg (24 hr) extended-release tablet | $1.63 | $49.03 / 30 tablets | ||
| 10 mg/mL oral suspension | Not priced this week | |||
| 200 mg tablet | $0.1470 | $4.41 / 30 tablets | ||
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Nevirapine
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use NEVIRAPINE TABLETS safely and effectively. See full prescribing information for NEVIRAPINE TABLETS. NEVIRAPINE tablets, USP for oral use. Initial U.S. Approval: 1996
WARNING: LIFE-THREATNING (INCLUDING FATAL) HEPATOTOXICITY and SKIN REACTIONS
HEPATOTOXICITY:
Severe, life-threatening, and in some cases fatal hepatotoxicity, particularly in the first 18 weeks, has been reported in patients treated with nevirapine. In some cases, patients presented with non-specific prodromal signs or symptoms of hepatitis and progressed to hepatic failure. These events are often associated with rash. Female gender and higher CD4
+ cell counts at initiation of therapy place patients at increased risk; women with CD4
+ cell counts greater than 250 cells/mm
3, including pregnant women receiving nevirapine in combination with other antiretrovirals for the treatment of HIV-1 infection, are at the greatest risk. However, hepatotoxicity associated with nevirapine use can occur in both genders, all CD4
+ cell counts and at any time during treatment. Hepatic failure has also been reported in patients without HIV taking nevirapine for post-exposure prophylaxis (PEP). Use of nevirapine for occupational and non-occupational PEP is contraindicated
[see
Contraindications (4)]
. Patients with signs or symptoms of hepatitis, or with increased transaminases combined with rash or other systemic symptoms, must discontinue nevirapine and seek medical evaluation immediately
[see
Warnings and Precautions (5.1)]
.
SKIN REACTIONS:
Severe, life-threatening skin reactions, including fatal cases, have occurred in patients treated with nevirapine. These have included cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions characterized by rash, constitutional findings, and organ dysfunction. Patients developing signs or symptoms of severe skin reactions or hypersensitivity reactions must discontinue nevirapine and seek medical evaluation immediately. Transaminase levels should be checked immediately for all patients who develop a rash in the first 18 weeks of treatment. The 14-day lead-in period with nevirapine 200 mg daily dosing has been observed to decrease the incidence of rash and must be followed
[see
Warnings and Precautions (5.2)]
.
MONITORING FOR HEPATOTOXICITY AND SKIN REACTIONS:
Patients must be monitored intensively during the first 18 weeks of therapy with nevirapine to detect potentially life-threatening hepatotoxicity or skin reactions. Extra vigilance is warranted during the first 6 weeks of therapy, which is the period of greatest risk of these events. Do not restart nevirapine following clinical hepatitis, or transaminase elevations combined with rash or other systemic symptoms, or following severe skin rash or hypersensitivity reactions. In some cases, hepatic injury has progressed despite discontinuation of treatment.
WARNING: LIFE-THREATENING (INCLUDING FATAL) HEPATOTOXICITY and SKIN REACTIONS
See full prescribing information for complete boxed warning.
Fatal and non-fatal hepatotoxicity have been reported in patients taking nevirapine tablets. Discontinue immediately if clinical hepatitis or transaminase elevations combined with rash or other systemic symptoms occur. Do not restart nevirapine tablets after recovery. (
5.1)
Fatal and non-fatal skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and hypersensitivity reactions, have been reported. Discontinue immediately if severe skin reactions, hypersensitivity reactions, or any rash with systemic symptoms occur. Check transaminase levels immediately for all patients who develop a rash in the first 18 weeks of treatment. Do not restart nevirapine tablets after recovery. (
5.2)
Monitoring during the first 18 weeks of therapy is essential. Extra vigilance is warranted during the first 6 weeks of therapy, which is the period of greatest risk of these events. (
5.1,
5.2)
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Generic makers
- 9 approved generic applications on the market
Nevirapine questions
How much does nevirapine cost without insurance?
Pharmacies pay about $4.41 for 30 tablets of nevirapine 200 mg tablet ($0.1470 per tablet). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $15.57. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is nevirapine in shortage?
No shortage is reported for nevirapine right now. We check the national shortage list every day.
Has nevirapine been recalled?
2 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the nevirapine label last change?
The official label was last updated on August 5, 2022 (version 15). See what changed.
Talk about nevirapine
No comments yet. Questions, tips, what worked for you - start the conversation.